Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open-label Study of TAK-659 Monotherapy in East Asian Adults With Non-Hodgkin Lymphoma
jRCT2080223623Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of mivavotinib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (3 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-659 (dose-limiting toxicities and adverse events) and Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Started Aug 2017; status: completed.
02
Drugs
mivavotinib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2080223623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223623.